Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX

Pacira Pharmaceuticals Stock Price & Analysis

280 Followers

PCRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$46.03 - $82.16
Previous Close$49.69
Volume105.11K
Average Volume (3M)386.48K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$328.73M
Total Debt (Recent Filing)$821.64M
Price to Earnings (P/E)125.6
Beta0.43
Next EarningsMar 01, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)0.40
Shares Outstanding45,882,088
R-Squared0.13
Standard Deviation0.12
10 Day Avg. Volume444,084
30 Day Avg. Volume386,475
Price to Book (P/B)71.78
Price to Sales (P/S)3.49
Price to Cash Flow (P/CF)19.90
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside50.15% Upside
Rating ConsensusStrong Buy
Alpha0.00785
Number of Analyst Covering7


Financials


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

PCRX FAQ

What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $46.03 and its highest was $82.16 in the past 12 months.
    What is Pacira Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Pacira Pharmaceuticals’s upcoming earnings report date?
    Pacira Pharmaceuticals’s upcoming earnings report date is Mar 01, 2023 which is in 92 days.
      How were Pacira Pharmaceuticals’s earnings last quarter?
      Pacira Pharmaceuticals released its earnings results on Nov 03, 2022. The company reported $0.64 earnings per share for the quarter, missing the consensus estimate of $0.767 by -$0.127.
        Is Pacira Pharmaceuticals overvalued?
        According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Pacira Pharmaceuticals pay dividends?
          Pacira Pharmaceuticals does not currently pay dividends.
          What is Pacira Pharmaceuticals’s EPS estimate?
          Pacira Pharmaceuticals’s EPS estimate is $0.96.
            How many shares outstanding does Pacira Pharmaceuticals have?
            Pacira Pharmaceuticals has 45,882,088 shares outstanding.
              What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
              Pacira Pharmaceuticals reported an EPS of $0.64 in its last earnings report, missing expectations of $0.767. Following the earnings report the stock price went down -2.727%.
                Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
                Among the largest hedge funds holding Pacira Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Pacira Pharmaceuticals’s shares valued at 16M.

                  ---

                  Pacira Pharmaceuticals Stock Smart Score

                  5
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -8.40%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  2.81%
                  Trailing 12-Months
                  Asset Growth
                  27.90%
                  Trailing 12-Months
                  The Pacira Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Pacira Pharmaceuticals

                  Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Johnson & Johnson
                  Eli Lilly & Co
                  Pfizer
                  Merck & Company
                  Bristol Myers

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis